Rockwell Medical Q3 2024 net income $1.7M, raises guidance; largest customer revenue expected to decline $31-38M in 2025

ROCKWELL MEDICAL, INC.

2024-Q3 EPS reported $0.01 revenue$76,824,000

Net product sales $28.3M (+31% YoY); gross profit $6.2M (+183%); gross margin 22% vs 9%.
Net income $1.7M vs loss $1.9M in Q3 2023; adjusted EBITDA $2.8M vs negative $1.2M.
Cash from operations $4.3M; cash and equivalents $18.3M, up from $11.9M at June 30.
2024 guidance raised: net sales $98-101M, gross profit $15-17M, adjusted EBITDA $4-5M.
Largest customer extended through Dec 2025 but expects volume decline of $31-38M in 2025; company aims to offset with new contracts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.